Biztoc.com

'Money Printing' Will Lift Bitcoin to $250K This Year: Arthur Hayes

The Japan Times

China warns US not to ‘play with fire’ over Taiwan

ZyCrypto

AI could soon consume more electricity than Bitcoin mining and entire countries

Biztoc.com

Onvo's May deliveries up at least 40%, despite 40% reduction in sales staff, says William Li

Biztoc.com

No Real Raise After Five Years? United Flight Attendants Settle For Just An Inflation Adjustment

Biztoc.com

China warns US not to ‘play with fire’ on Taiwan as Hegseth brands Beijing ‘imminent’ threat

CoinDesk

Microsoft takes down malware found on 394,000 Windows PCs

The Jerusalem Post

RBI likely to cut repo rate by 25 bps on June 6 amid easing inflation

Biziday.ro

Fed Governor Lisa Cook sees tariffs raising inflation and complicating rate policy

Biztoc.com

Thoma Bravo raises $34 billion for buyout funds

The Japan Times

Liberal Lee Jae-myung wins South Korean presidential election

ZyCrypto

Japanese Interest in Cardano (ADA) Shoots up, ADA/JPY Pairs Hit New Levels Globally

Biztoc.com

CrowdStrike vs. Palo Alto Networks — why Wall Street values these stocks so differently

Biztoc.com

JPMorgan’s Jamie Dimon Sees Bond Market Crack — Why And What To Do

Biztoc.com

Here's How Much You Would Have Made Owning Shopify Stock In The Last 10 Years

CoinDesk

New Hampshire Tops List of Most Crypto-Friendly U.S. States: Study

The Jerusalem Post

How closing Arab refugee camps would undercut the global intifada

Biziday.ro

FT: Compania de inteligență artificială a lui Elon Musk, xAI, lansează o vânzare de acțiuni de 300 de milioane de dolari. Aceasta va ridica valoarea xAI la 113 miliarde de dolari, în momentul în care miliardarul a anunțat se va concentra din nou pe companiile sale.

Yahoo Entertainment

Trump promises to hike steel and aluminum tariffs to 50% starting Wednesday. Here's what we know

Xataka.com

China se perfila como líder en tecnología médica: la UE está a un paso de vetarla en sus grandes licitaciones, según Reuters

GlobeNewswire

Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors